New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.
The company takes another project from Taris into phase 3 as it chases a $5bn market.
A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.